Schizophrenia is one of the most complex and serious psychiatric disorders. Despite decades of research, many of its causes remain unexplained. In recent years, interest in biomarkers has grown considerably, as they offer the possibility of putting diagnosis, prognosis and therapy on a more objective and personalized basis. Genetic, neurobiological, developmental and epigenetic factors play a central role here. This article summarizes the current state of research and shows perspectives on how biomarkers could revolutionize the clinical care of patients with schizophrenia in the future.
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- Osgood-Schlatter Disease
Clinical Presentation, Diagnosis, and Treatment
- Cardiovascular Risk in Rheumatoid Arthritis
What is the most dangerous thing for RA?
- Antisense oligonucleotide for severe hypertriglyceridemia
Reduced Incidence of Acute Pancreatitis
- Hereditary Transthyretin Amyloidosis with Polyneuropathy
New Treatment Options for ATTRv-PN
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach
Slowing the loss of β-cell function and delaying the progression of the disease
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain